---
layout: post
title: "明德生物2021年度净利润预增177%-220%"
date: 2022-01-04 20:48:09 +0800
categories: shanghaizhengquanbao·zhongguozhengquanwang
tags: 上海证券报·中国证券网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002932" data-code="002932|0|2" data-code2="002932|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002932&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002932_0" data-code="K 002932|0|2" data-code2="K 002932|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>明德生物披露业绩预告。公司预计2021年盈利130,000万元-150,000万元，比上年同期增长177.23%-219.88%。报告期内，公司新冠核酸检测试剂销售大幅增长；海外新冠检测试剂外贸订单及相关收入大幅增长。<br /></p><p class="em_media">（文章来源：上海证券报·中国证券网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201042235781457>

[返回上海证券报·中国证券网新闻](//finews.withounder.com/category/shanghaizhengquanbao·zhongguozhengquanwang.html)｜[返回首页](//finews.withounder.com/)